Studying the antidepressant effects of intravenous ketamine in patients with major depressive disorder

Randomised, interventional Phase II/III study of intravenous ketamine 0.5 mg/kg given once weekly for two weeks as an adjunctive treatment in patients with major depressive disorder on stable oral antidepressants.

Comparators include intravenous scopolamine 4 µg/kg (weekly for two weeks) and saline placebo; outcomes include change in MADRS and CGI at baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.